Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479191 | 0.81 | SLC16A3 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL4479186 | 0.81 | SLC16A3 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL13635243 | 0.81 | KMT2A (0.35) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL4381696 | 0.81 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL22070999 | 0.81 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL4381700 | 0.81 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL28388395 | 0.80 | CYP4F2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL17040979 | 0.79 | SMYD2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL10380887 | 0.79 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2KLK7 | |
| SCHEMBL22070702 | 0.78 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538131-B2 | 2-{-3-′2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, PPARD | CYP3A4 807/4885HTT 2972/4885SMN1; SMN2 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.